Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
|Videos|September 15, 2022
VEW 2022: New dark adaptation modality and other pipeline updates from Heru
Author(s)Kassi Filkins, Editor
Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.
Advertisement
Brandon Barber, chief marketing officer for Heru, sat down with Optometry Times® editor, Kassi Jackson, to share about the company's new AMD portfolio expansion, and other items in the pipeline.
Key takeaways from the interview:
- Heru's latest dark adaptation modality. This new technology allows Heru to offer the only AMD portfolio available on the market.
- The company is providing cloud-based updates for their platform on a weekly and monthly basis to improve customer and patient outcomes.
- New therapeutic technology is coming out of their research facility in Bascom Palmer Eye Institute, including AR platform adaptations to improve eye defects that lead to limited vision for patients.
- Barber said that in the next 24 to 36 months, there will be advancements in the areas of AR and VR.
- These new and coming advancements improve patient experience, as well as will improve the ability for optometrists to "speed more patients through their practice," according to Barber.
Advertisement
Related to this article
Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."
Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, details a lack of research exploring the intersection of hormones and ocular health in women and what health care as a whole should investigate next.
Michael Cymbor, OD, FAAO, gives an overview of a rapid fire lecture he gave in collaboration with Andrew Rixon OD, FAAO; Austin Lifferth, OD, FAAO; and Derek MacDonald, OD, FAAO, at AAOpt 2026.
Coats explains how neurotrophic keratitis, Demodex blepharitis, cosmetic habits, and mucus fishing complicate dry eye disease.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: The underutilization of latanoprostene bunod 0.024% in glaucoma care
2
AAOpt 2026: Insights into perimenopause and presbyopia
3
AAOpt 2026: The human cost of dry eye
4
AAOpt 2026: How DOT lenses affect children’s everyday vision
5